Item Type | Name |
Academic Article
|
A young woman with fever, headache, and lymphadenopathy.
|
Academic Article
|
Cytomegalovirus pneumonia in patients with lymphoma.
|
Academic Article
|
Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality.
|
Academic Article
|
Viral infection or reactivation in patients during treatment with dasatinib: a call for screening?
|
Academic Article
|
Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention.
|
Academic Article
|
Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry.
|
Academic Article
|
Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients.
|
Academic Article
|
Human herpesvirus-6 DNAemia in immunosuppressed adult patients with leukemia at risk for mold infection.
|
Academic Article
|
Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center.
|
Academic Article
|
Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.
|
Academic Article
|
Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection.
|
Academic Article
|
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.
|
Academic Article
|
Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study.
|
Academic Article
|
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
|
Concept
|
Herpesvirus 1, Human
|
Concept
|
Cytomegalovirus Infections
|
Concept
|
Herpesvirus 6, Human
|
Concept
|
Cytomegalovirus
|
Concept
|
Herpesvirus 3, Human
|
Academic Article
|
Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.
|
Academic Article
|
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
|
Academic Article
|
CMV prophylaxis in hematopoietic-cell transplantation.
|
Academic Article
|
Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
|
Academic Article
|
Human herpesvirus 6.
|
Academic Article
|
Utility of the Enzyme-Linked Immunospot Interferon-?-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
|
Academic Article
|
Utility of the enzyme-linked immunospot interferon-γ- release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients
|
Academic Article
|
Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients
|
Academic Article
|
The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation
|
Academic Article
|
Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.
|
Academic Article
|
The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
|
Academic Article
|
Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
|
Academic Article
|
A MULTICENTER, LONGITUDINAL, INTERVENTIONAL, DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS RESIDING IN REMOTE AREAS: LESSONS LEARNED FROM THE LATE CYTOMEGALOVIRUS PREVENTION TRIAL.
|
Academic Article
|
How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.
|
Academic Article
|
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
|
Academic Article
|
Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
|
Academic Article
|
Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials.
|
Academic Article
|
Reply to Gim?nez et al.
|
Academic Article
|
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
|
Academic Article
|
The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
|
Academic Article
|
HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
|
Academic Article
|
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
|
Academic Article
|
Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.
|
Academic Article
|
Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management.
|
Academic Article
|
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.
|
Academic Article
|
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
|
Academic Article
|
Disseminated cytomegalovirus infection with bilateral adrenal pseudotumors masquerading as recurrent hematologic malignancy.
|
Academic Article
|
Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant.
|
Academic Article
|
Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.
|
Academic Article
|
Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program.
|
Academic Article
|
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.
|
Academic Article
|
Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
|
Academic Article
|
American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation.
|
Academic Article
|
American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation.
|
Academic Article
|
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
|
Academic Article
|
Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression.
|
Academic Article
|
Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium.
|
Academic Article
|
Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies.
|
Academic Article
|
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
|
Academic Article
|
CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir.
|
Academic Article
|
Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
|